{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-307541","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2025-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.227671+00:00","generated_at":"2026-05-16T14:49:57.188646+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioAge reports positive Phase 1 interim data for NLRP3 inhibitor BGE-102; 90-98% IL-1β suppression","bullets":["BGE-102 well-tolerated across all doses (SAD: 10-120 mg; MAD: 60-120 mg); AEs mild/moderate, all resolved.","90-98% suppression of IL-1β at Day 14; doses ≥60 mg exceeded IC90 in CSF, demonstrating high brain penetration.","Phase 1 expanded to MAD cohorts in obese participants with elevated hsCRP; data expected 1H26.","Phase 2a proof-of-concept planned for 1H26 (100 patients, 12 weeks, primary endpoint % hsCRP change); data readout 2H26.","Pharmacokinetics support once-daily oral dosing; dose proportionality observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-307541","json":"https://secwatch.observer/filing/0001193125-25-307541.json","markdown":"https://secwatch.observer/filing/0001193125-25-307541.md","text":"https://secwatch.observer/filing/0001193125-25-307541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000119312525307541/0001193125-25-307541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000119312525307541/bioa-20251204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:49:57.188646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}